Sugi Predict

Sugi Predict / Compounds / SCHEMBL1634757

SCHEMBL1634757

SCHEMBL1634757

O=C1CCCN1c1cccc(Br)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.62
▸ CYP3A4 P08684 2/20 0.62
▸ CYP2C9 P11712 2/20 0.62
▸ CYP1A2 P05177 1/20 0.62
▸ CYP2D6 P10635 1/20 0.62
▸ HPGD P15428 1/20 0.62
▸ CYP2C19 P33261 1/20 0.62
▸ ALOX5 P09917 1/20 0.56
▸ MEN1 O00255 6/20 0.55
▸ KMT2A Q03164 6/20 0.55
▸ GAA P10253 1/20 0.55
▸ RAB9A P51151 3/20 0.51
▸ SMN1; SMN2 Q16637 3/20 0.51
▸ NPC1 O15118 2/20 0.51
▸ L3MBTL1 Q9Y468 2/20 0.51
▸ TSHR P16473 2/20 0.51
▸ POLB P06746 1/20 0.51
▸ DUSP3 P51452 1/20 0.51
▸ PTPN5 P54829 1/20 0.51
▸ PTPN11 Q06124 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29930250 1.00 ALDH1A1 (0.62) ALDH1A1CYP3A4CYP2C9CYP1A2CYP2D6
SCHEMBL21805910 0.95 ALDH1A1 (0.56) ALDH1A1CYP3A4CYP2C9CYP1A2CYP2D6
SCHEMBL17870929 0.89 ALDH1A1 (0.54) ALDH1A1CYP3A4CYP2C9CYP1A2CYP2D6
SCHEMBL6028118 0.81 ALDH1A1 (0.64) ALDH1A1CYP3A4CYP2C9CYP1A2CYP2D6
SCHEMBL519856 0.81 ALDH1A1 (0.64) ALDH1A1CYP3A4CYP2C9CYP1A2CYP2D6
SCHEMBL2518610 0.80 ALDH1A1 (0.59) ALDH1A1CYP3A4CYP2C9CYP1A2CYP2D6
SCHEMBL12460062 0.79 ALOX5 (0.49) ALDH1A1CYP3A4CYP2C9CYP1A2CYP2D6
SCHEMBL1616661 0.79 ALDH1A1 (0.62) ALDH1A1CYP3A4CYP2C9CYP1A2CYP2D6
SCHEMBL1459903 0.79 ALDH1A1 (0.62) ALDH1A1CYP3A4CYP2C9CYP1A2CYP2D6
SCHEMBL1543125 0.79 ALDH1A1 (0.67) ALDH1A1CYP3A4CYP2C9CYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4709720-A1 INHIBITORS AND DEGRADERS OF PIP4K PROTEIN Larkspur Biosciences, Inc. (US) 2026-03-18 — — EP disclosed
US-20250353851-A1 PURINES AND METHODS OF THEIR USE KINETA INC (US) 2025-11-20 — — US disclosed
US-20250313574-A1 SIALIC ACID DERIVATIVES AND METHODS OF USING SAME EISAI R&D MANAGEMENT CO., LTD. (JP) 2025-10-09 — — US disclosed
EP-4594318-A1 AKT1 MODULATORS Alterome Therapeutics, Inc. (US) 2025-08-06 — — EP disclosed
US-20250197375-A1 PYRIMIDINES AND METHODS OF THEIR USE Kineta, Inc. 2025-06-19 — — US disclosed
EP-4536653-A2 SIALIC ACID DERIVATIVES AND METHODS OF USING SAME Eisai R&D Management Co., Ltd. (JP) 2025-04-16 — — EP disclosed
US-20250092040-A1 AKT1 MODULATORS ALTEROME THERAPEUTICS, INC. 2025-03-20 — — US disclosed
CN-119031913-A Purine and methods of use thereof 奇尼塔公司 2024-11-26 — — CN disclosed
WO-2024233846-A1 INHIBITORS AND DEGRADERS OF PIP4K PROTEIN LARKSPUR BIOSCIENCES, INC. (US) 2024-11-14 — — WO disclosed
CN-118922188-A Pyrimidine and methods of use thereof 奇尼塔公司 2024-11-08 — — CN disclosed
US-20090215724-A1 Pyrrolopyrazine kinase inhibitors ROCHE PALO ALTO LLC 2009-08-27 — — US disclosed
US-20090215724-A1 Pyrrolopyrazine kinase inhibitors ROCHE PALO ALTO LLC 2009-08-27 — — US disclosed
WO-2009007747-A2 HYDANTOIN DERIVATIVES USED AS MMP12 INHIBITORS ASTRAZENECA AB (SE) 2009-01-15 — — WO disclosed
EP-1951719-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-08-06 — — EP disclosed
EP-1742907-A4 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS INC (US) 2008-01-02 — — EP disclosed
WO-2007056469-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 — — WO disclosed
EP-1742907-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2007-01-17 — — EP disclosed
WO-2005107762-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2005-11-17 — — WO disclosed
EP-1438288-A1 SUBSTITUTED THIOACETAMIDES CEPHALON, INC. (US) 2004-07-21 — — EP disclosed
WO-2003037853-A1 SUBSTITUTED THIOACETAMIDES CEPHALON, INC. (US) 2003-05-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250313574-A1 SIALIC ACID DERIVATIVES AND METHODS OF USING SAME NEU1, NEU2, NEU4 ALDH1A1 474/4885CYP3A4 2220/4885CYP2C9 2725/4885
US-20250197375-A1 PYRIMIDINES AND METHODS OF THEIR USE TDP1, TYMP, TARDBP ALDH1A1 2220/4885CYP3A4 4071/4885CYP2C9 4491/4885
US-20090215724-A1 Pyrrolopyrazine kinase inhibitors SYK, ZAP70, JAK1 ALDH1A1 3672/4885CYP3A4 2523/4885CYP2C9 3169/4885
US-20250092040-A1 AKT1 MODULATORS AKT1S1, AKT1, AKT2 ALDH1A1 4692/4885CYP3A4 4570/4885CYP2C9 4778/4885
US-20250353851-A1 PURINES AND METHODS OF THEIR USE TDP1, TDP2, PIKFYVE ALDH1A1 4617/4885CYP3A4 3989/4885CYP2C9 4445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.